NasdaqCM - Nasdaq Real Time Price USD

Vivani Medical, Inc. (VANI)

1.0950 +0.0050 (+0.46%)

As of 3:48:05 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Vivani Medical Announces Participation in Upcoming Investor Conferences

GlobeNewswire 21d ago

VANI
+0.46%
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

GlobeNewswire 2mo ago

VANI
+0.46%
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

MarketBeat 3mo ago

VANI
+0.46%
NVO
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

GlobeNewswire 3mo ago

VANI
+0.46%
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

GlobeNewswire 3mo ago

VANI
+0.46%
NOVO-B.CO
Vivani strikes reverse-merger agreement with ClearOne for BCI business

Medical Device Network 3mo ago

VANI
+0.46%
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

GlobeNewswire 4mo ago

VANI
+0.46%
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

GlobeNewswire 4mo ago

VANI
+0.46%
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

GlobeNewswire 5mo ago

VANI
+0.46%
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire 5mo ago

VANI
+0.46%
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Zacks 6mo ago

VANI
+0.46%
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant

Pharmaceutical Technology 3mo ago

NOVO-B.CO

VANI
+0.46%

Performance Overview

Return	VANI	S&P 500 (^GSPC)
YTD	-11.38%	+10.32%
1-Year	-32.30%	+10.40%
3-Year	+4.81%	+74.90%

U.S. markets close in 3m

Vivani Medical, Inc. (VANI)

Vivani Medical Announces Participation in Upcoming Investor Conferences

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani strikes reverse-merger agreement with ClearOne for BCI business

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant